Literature DB >> 10475979

Presentation of protective antigen to the mouse immune system: immune sequelae.

E D Williamson1, R J Beedham, A M Bennett, S D Perkins, J Miller, L W Baillie.   

Abstract

Protective antigen (PA), the major protective component of the existing vaccine, is a potent immunogen. Protective antigen in alhydrogel induced a high serum IgG titre (> log10 4) in both the C57B16 and Balb/c mouse and the predominant subclass of antibody induced was IgG1, indicating that the response to PA was predominantly Th2 directed. When plasmid DNA encoding PA was used to immunize the Balb/c mouse, a low serum IgG titre was detected (</=log10 1), which was slightly increased by boosting with plasmid DNA. However, when mice immunized with plasmid DNA were later boosted with rPA, a significant and rapid increase in titre (up to threefold) was observed. Priming mice with PA-encoding plasmid DNA may be a mechanism of enhancing and accelerating the immune response to PA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475979     DOI: 10.1046/j.1365-2672.1999.00901.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  7 in total

1.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.

Authors:  Helen C Flick-Smith; Nicola J Walker; Paula Gibson; Helen Bullifent; Sarah Hayward; Julie Miller; Richard W Titball; E Diane Williamson
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

3.  Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Authors:  Helen C Flick-Smith; Jim E Eyles; Richard Hebdon; Emma L Waters; Richard J Beedham; Tony J Stagg; Julie Miller; H Oya Alpar; Les W J Baillie; E Diane Williamson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

5.  Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.

Authors:  Nareen Abboud; Arturo Casadevall
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

Review 6.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

7.  Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.

Authors:  T Scott Devera; Sunil K Joshi; Lindsay M Aye; Gillian A Lang; Jimmy D Ballard; Mark L Lang
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.